Get the Stockscreener App
4.59
2.34%
-0.11
After Hours:
4.59
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $4.59, with a volume of 1.72M.
It is down -2.34% in the last 24 hours and down -8.57% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$4.70
Open:
$4.73
24h Volume:
1.72M
Relative Volume:
0.73
Market Cap:
$2.00B
Revenue:
$9.47B
Net Income/Loss:
$-178.00M
P/E Ratio:
-9.5625
EPS:
-0.48
Net Cash Flow:
$1.01B
1W Performance:
-15.31%
1M Performance:
-8.57%
6M Performance:
-50.86%
1Y Performance:
-33.96%
1-Day Range:
$4.52
$4.77
1-Week Range:
$4.52
$5.385
52-Week Range:
$3.96
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
4.59 | 2.00B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Bausch health outlines 2025 guidance with 4-5% revenue and EBITDA growth amid strategic refinancing - MSN
Scar Treatment Market Detailed In New Research Report 2025 | - openPR.com
Bausch Health Companies Inc. (BHC): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Bausch Health shares fall 39% following InvestingPro’s overvalued warning By Investing.com - Investing.com
Bausch + Lomb Brief: Says Received European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens - marketscreener.com
Bausch Health (BHC) Data Highlights Reduced Rehospitalization wi - GuruFocus
Bausch Health (BHC) Data Highlights Reduced Rehospitalization with Xifaxan Use | BHC Stock News - GuruFocus
Bausch Health Up 3.5% In US Premarket As Says New Analysis Suggests efficacy of Xifaxan - marketscreener.com
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization - voiceofalexandria.com
Bausch Health (BHC) Target Price Reduced by Raymond James | BHC Stock News - GuruFocus
Bausch Health (BHC) Faces Revised Price Target by Raymond James | BHC Stock News - GuruFocus
Bausch Health price target cut to $8 by Raymond James - Investing.com Nigeria
Dry Eye Syndrome Treatment Market Set to Witness Significant - openPR.com
BHC: RBC Capital Raises Price Target for Bausch Health Companies - GuruFocus
Bausch Health Companies Inc. (NYSE:BHC) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail
Bausch Health Companies First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Psoriasis Market: Epidemiology, Therapies, Companies, - openPR.com
RBC on Bausch Health's Q1 - marketscreener.com
Bausch Health Q1 Earnings And Revenues Miss Estimates, Stock Down - Barchart.com
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down - Zacks Investment Research
Bausch Health Companies Inc. SEC 10-Q Report - TradingView
Bausch: Q1 Earnings Snapshot - The Washington Post
Bausch Health Reports Q1 2025 Financial Results - TipRanks
Bausch Health Companies Q1 2025 Earnings Call Transcript - MarketBeat
Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Bausch Health Companies Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bausch Health Q1 2025 slides: revenue up 6%, EBITDA grows 14% excluding B+L - Investing.com
Bausch Health Companies Inc. 2025 Q1ResultsEarnings Call Presentation (NYSE:BHC) - Seeking Alpha
Bausch Health Down 3.8% After Hours as It Reports a Lower Q1 Adjusted Profit - marketscreener.com
Bausch Health Reports Strong Q1 2025 Results with Revenue Growth and Strategic Refinancing - TipRanks
Bausch Health (BHC) Pre-Earnings Options Activity Indicates Anti - GuruFocus
Bausch Health Reports 8th Consecutive Growth Quarter, Completes $7.9B Refinancing Deal - Stock Titan
Bausch Health Announces First Quarter 2025 Results - The Globe and Mail
Bausch + Lomb Brief: Updating FY25 Guidance to Reflect Estimated One-Time Impact of enVista Intraocular Lenses Voluntary Recall and Impact of FX - marketscreener.com
Health Canada approves Bausch Health’s skin tightening device - Investing.com
Bausch Health Companies Q1 2025 Earnings Preview - MSN
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Bausch Health Companies Inc. (BHC) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Hyperopia Market, Epidemiology, Therapies, Companies, - openPR.com
Bausch Health's Skin Tightening System Gets Health Canada Clearance - marketscreener.com
BHC Receives Canadian Approval for Advanced Thermage FLX Device - GuruFocus
Bausch Health Announcing Health Canada Clearance of Solta Medical's Thermage FLX System - marketscreener.com
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System - voiceofalexandria.com
Revolutionary Skin Tightening Device Thermage FLX Gets Health Canada Green Light: 25% Faster Treatments - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Onychomycosis Drug Market Emerging Trends and Growth Prospects - openPR.com
Bausch Health Says Carl Icahn Has 34% Economic Interest In Its Outstanding Shares - MSN
Bausch Health jumps after Carl Icahn’s 34% stake - MSN
BAUSCH HEALTH COMPANIES INC. (NYSE: BHC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Companies Inc. - ACCESS Newswire
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):